Report Id: SNS/HC/1264 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Clinical Decision Support Systems Market Size was valued at USD 5.08 billion in 2022 and is expected to reach USD 11.04 billion by 2030, and grow at a CAGR of 10.2% over the forecast period 2023-2030.
One of the important factors driving market expansion is the growing need for high-quality care and integrated, dependable technical solutions. Hospitals and healthcare institutions are increasingly adopting information technology, and various governments throughout the world are taking positive steps to boost the sector. The FDA, for example, regulates clinical decision support systems quite carefully. As a result, platforms that have been released or in the development phase must meet FDA and CE Mark requirements. In addition, competitors must ensure that information technology and cyber regulations are not broken in order to ensure the integrity of their products.
Medication errors are becoming more common.
Hospitals are becoming more numerous.
Data-driven technologies are becoming increasingly popular.
The number of emergency department (ED) visits is decreasing.
Data Privacy Threat
Implementation Costs Are Exorbitant
Healthcare Information Technology Advancements
Asian countries in transition
IMPACT OF COVID-19
Medical practices of all sizes are under tremendous strain as a result of the COVID-19 pandemic, and healthcare facilities around the world have been overburdened by the high number of patients who see them on a regular basis. In various nations around the world, the onset of this epidemic has fueled demand for effective detection and treatment equipment. Clinical decision support systems have proven to be quite useful in this area, as they allow healthcare personnel to monitor patients using non-invasive digitally connected equipment like home blood pressure monitors and pulse oximeters. Furthermore, due to the disease's rapid spread around the world, hospital wards and healthcare staff are in limited supply. The need for linked medical devices for vital sign monitoring has risen as a result.
The COVID-19 epidemic has also raised the requirement for social distancing between physicians and patients, driving demand for distant patient monitoring and telemedicine solutions, as well as the necessity for accurate and rapid patient health record interchange. Several market companies have included COVID-19-related functionality into their existing EHRs, which are being made available to consumers for free.
The demand for EMR and EHR solutions to manage sophisticated patient data has expanded as patient volumes have grown. As a result, hospitals are focusing more on enhancing their capabilities by connecting multiple hospital systems with EHRs.
Due to its low cost and simplicity, standalone CDSS had the highest revenue share in 2021. Its popularity is due to its ease of usage in hospitals and therapeutic settings. All throughout projected period, the solitary category will continue to dominate the market. CDSS items can be utilized autonomously or related to an EHR or CPOE, or both.
Drug allergy notifications accounted for approximately 25.0 percent of total revenue. Because many people are allergic to certain pharmaceuticals, it is critical to have systems in place that provide allergy alerts. The prevalence of allergies, particularly medication allergies, is increasing. A medical error can occur during the process of prescribing, dispensing, or administering a prescription, and it can have serious consequences, such as giving medication to a patient who has a documented allergy to that substance.
The services segment accounted for almost 41.0 percent of total revenue. This is due to regular programe upgrades and the knowledge base available for use. The support of parts and their adornments is one of CDSS's administrations. It incorporates equipment and programming overhauls, as well as admittance to an information data set that covers the latest leap forwards and medications.
The on-premise systems category accounted for nearly 41.0 percent of total sales. Due to tremendous advancement in information technology, cloud-based systems represented the second-largest revenue share in 2021, with potential applications in the healthcare industry. The expansion of this segment is fueled by factors such as reliability and cost-effectiveness.
Some of the major key players are as follows: IBM Corporation, Allscripts Healthcare, LLC, Koninklijke Philips N.V. (Royal Philips), McKesson Corporation, NextGen Healthcare Inc., Cerner Corporation, Siemens Healthineers GmbH, Wolters Kluwer N.V., athenahealth, Inc., Agfa-Gevaert Group, and other players.
Integrated E.H.R. with CDSS
Integrated CPOE with CDSS
Integrated CDSS with CPOE & E.H.R.
By Application type
Drug Allergy Alerts
Drug Dosing Support
By Delivery Type
By Component type
North America, Europe, Asia Pacific (APAC), and the Rest of the World are the segments of the clinical decision support system market. Over the next five years, the market in APAC is predicted to develop at the fastest rate. The CDSS market in Asia is predicted to increase due to factors such as the presence of a large ageing population, improved government laws, a high burden of chronic diseases, and the increasing focus of key industry players on emerging Asian countries.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 5.08 Billion|
|Market Size by 2030||US$ 11.04 Billion|
|CAGR||CAGR of 10.2% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Product (Standalone CDSS, Integrated E.H.R. with CDSS, Integrated CPOE with CDSS, Integrated CDSS with CPOE & E.H.R.)
• By Application type (Clinical Reminders, Drug-drug Interactions, Clinical Guidelines, Drug Allergy Alerts, Drug Dosing Support, Others)
• By Delivery Type (Cloud-based Systems, Web-based Systems, On-premise Systems)
• By Component type (Software, Hardware, Services)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||IBM Corporation, Allscripts Healthcare, LLC, Koninklijke Philips N.V. (Royal Philips), McKesson Corporation, NextGen Healthcare Inc., Cerner Corporation, Siemens Healthineers GmbH, Wolters Kluwer N.V., athenahealth, Inc., Agfa-Gevaert Group, and other players.|
|DRIVERS||• Medication errors are becoming more common.
• Hospitals are becoming more numerous.
• Data-driven technologies are becoming increasingly popular.
|RESTRAINTS||• Data Privacy Threat
• Implementation Costs Are Exorbitant
Frequently Asked Questions (FAQ) :
Clinical Decision Support Systems Market Size was valued at USD 4.61 billion in 2021.
IBM Corporation, Allscripts Healthcare, LLC, Koninklijke Philips N.V. (Royal Philips), McKesson Corporation, NextGen Healthcare Inc., and Cerner Corporation are the key players in the Clinical Decision Support Systems Market.
Over the next five years, the market in APAC is predicted to develop at the fastest rate. The CDSS market in Asia is predicted to increase.
Medication errors are becoming more common, Hospitals are becoming more numerous, and Data-driven technologies are becoming increasingly popular all propelling the Clinical Decision Support Systems market forward.
Data Privacy Threat, Implementation Costs Are Exorbitant are the main restraints of the Clinical Decision Support Systems market.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
220.127.116.11 United Kingdom
18.104.22.168 South Korea
22.214.171.124 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 Forces Model
7. PEST Analysis
8. Clinical Decision Support Systems Market Segmentation, By Product
8.1 Standalone CDSS
8.2 Integrated E.H.R. with CDSS
8.3 Integrated CPOE with CDSS
8.4 Integrated CDSS with CPOE & E.H.R.
9. Clinical Decision Support Systems Market Segmentation, By Application type
9.1 Clinical Reminders
9.2 Drug-drug Interactions
9.3 Clinical Guidelines
9.4 Drug Allergy Alerts
9.5 Drug Dosing Support
10. Clinical Decision Support Systems Market Segmentation, By Delivery Type
10.1 Cloud-based Systems
10.2 Web-based Systems
10.3 On-premise Systems
11. Clinical Decision Support Systems Market Segmentation, By Component type
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13. Company Profiles
13.1 IBM Corporation
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 Allscripts Healthcare, LLC
13.3 Koninklijke Philips N.V. (Royal Philips)
13.4 McKesson Corporation
13.5 NextGen Healthcare Inc.
13.6 Cerner Corporation
13.7 Siemens Healthineers GmbH
13.8 Wolters Kluwer N.V.
13.9 thenahealth, Inc.
13.10 Agfa-Gevaert Group.
14. Competitive Landscape
14.1 Competitive Benchmark
14.2 Market Share Analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.